Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality TestingInvivoscribe Marketing2021-02-17T18:10:07-08:00November 17th, 2020|Read more
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaInvivoscribe Marketing2021-02-11T20:05:42-08:00October 30th, 2020|Read more
Plasticity of the human IgM repertoire in response to long‐term spaceflightInvivoscribe Marketing2021-02-11T20:09:45-08:00October 13th, 2020|Read more
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyInvivoscribe Marketing2021-02-11T20:11:02-08:00October 8th, 2020|Read more
Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtypeInvivoscribe Marketing2021-02-11T20:13:51-08:00August 27th, 2020|Read more
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in JapanInvivoscribe Marketing2021-02-26T19:11:02-08:00November 29th, 2018|Read more
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for QuizartinibInvivoscribe Marketing2022-09-23T16:52:06-07:00November 27th, 2018|Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in JapanInvivoscribe Marketing2021-02-26T19:11:48-08:00November 19th, 2018|Read more
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)Invivoscribe Marketing2021-02-26T19:12:02-08:00September 27th, 2018|Read more
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene PanelsInvivoscribe Marketing2021-02-26T19:12:15-08:00May 9th, 2018|Read more